APBK Capital
Contributor since: 2015
Company: APBK Capital
Dimension Therapeutics - A Key Partnership Could Mean Huge Success
Adesto Technologies: Trying To Be Trendy
Surgery Partners: Growing Surgical Demand Fueling Profits
Allegiance Bancshares - Growing Community Bank With Some IPO Upside
Digicel Group: Big Valuation On A Company With No Growth
Aclaris Therapeutics - A Sizable Market There For The Taking
NovoCure - Slashes IPO Price Range, A Great Value Now
CPI Card Group - Trying To Cash In On New Credit Card Regulations
Fuling Global - Making A Great Margin On Plastic Forks
Cerecor - Following In Big Footsteps Doesn't Mean This One Will Be A Blockbuster
Strongbridge Biopharma - Rare Diseases And Under-Served Markets Mean High Profits In Biotech
Performance Food Group - Fast Growth And Acquisition Potential
Mirna Therapeutics - Tons Of Future Potential But Lacking Clear Direction
Oasmia Pharmaceuticals - Approved In Russia, Ready For The Big Markets
Regenxbio - The First Biotech IPO In Weeks
Albertsons Could Be A Bargain Shopping Trip - IPO Outlook Series Q4 2015
Nabriva Therapeutics - An IPO With Blockbuster Potential
Penumbra - A Cheap Medical Device Company With Growth Potential
Juno Therapeutics- A Huge Valuation, But Is Now The Time To Buy?
CytomX Therapeutics Has Big Potential - IPO Outlook Series
Market Volatility Leaves Behind Bargain Cancer Biotech - Adaptimmune
Aduro Biotech - A Forgotten Biotech With Big Potential
Now Is The Time To Buy Etsy - IPO Review Series
IPO Outlook Series - Neiman Marcus - Growth Potential Galore
TerraForm Global - Major Price Drop Since IPO Creates Great Opportunity
IPO Outlook Series - Pure Storage: A Business Model That Fills A Very Large Void
IPO Outlook Series - Vizio - Get Ready For A Major Brand IPO
Boxlight: An IPO-Funded Merger With Plenty Of Upside
Houlihan Lokey - An Exciting Financial Services IPO Opportunity
Conifer Holdings - Leading Growth In Niche Insurance Markets
Global Blood Therapeutics - Unique Sickle Cell Therapy Could Have Big Payoff
Aimmune: Food Allergies Could Be A Thing Of The Past With This Biotech